B cells as a therapeutic target in autoimmune disease
Depleting B cells with anti-CD20 monoclonal antibodies emerges as a new therapeutic strategy in autoimmune diseases. Preliminary clinical studies suggest therapeutic benefits in patients with classic autoantibody-mediated syndromes, such as autoimmune cytopenias. Treatment responses in rheumatoid ar...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2003
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165047/ |
| id |
pubmed-165047 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-1650472003-07-12 B cells as a therapeutic target in autoimmune disease Goronzy, Jörg J Weyand, Cornelia M Commentary Depleting B cells with anti-CD20 monoclonal antibodies emerges as a new therapeutic strategy in autoimmune diseases. Preliminary clinical studies suggest therapeutic benefits in patients with classic autoantibody-mediated syndromes, such as autoimmune cytopenias. Treatment responses in rheumatoid arthritis have opened the discussion about whether mechanisms beyond the removal of potentially pathogenic antibodies are effective in B-cell depletion. B cells may modulate T-cell activity through capturing and presenting antigens or may participate in the neogenesis of lymphoid microstructures that amplify and deviate immune responses. Studies exploring which mechanisms are functional in which subset of patients hold the promise of providing new and rational treatment approaches for autoimmune syndromes. BioMed Central 2003 2003-03-19 /pmc/articles/PMC165047/ /pubmed/12723978 http://dx.doi.org/10.1186/ar751 Text en Copyright © 2003 BioMed Central Ltd |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Goronzy, Jörg J Weyand, Cornelia M |
| spellingShingle |
Goronzy, Jörg J Weyand, Cornelia M B cells as a therapeutic target in autoimmune disease |
| author_facet |
Goronzy, Jörg J Weyand, Cornelia M |
| author_sort |
Goronzy, Jörg J |
| title |
B cells as a therapeutic target in autoimmune disease |
| title_short |
B cells as a therapeutic target in autoimmune disease |
| title_full |
B cells as a therapeutic target in autoimmune disease |
| title_fullStr |
B cells as a therapeutic target in autoimmune disease |
| title_full_unstemmed |
B cells as a therapeutic target in autoimmune disease |
| title_sort |
b cells as a therapeutic target in autoimmune disease |
| description |
Depleting B cells with anti-CD20 monoclonal antibodies emerges as a new therapeutic strategy in autoimmune diseases. Preliminary clinical studies suggest therapeutic benefits in patients with classic autoantibody-mediated syndromes, such as autoimmune cytopenias. Treatment responses in rheumatoid arthritis have opened the discussion about whether mechanisms beyond the removal of potentially pathogenic antibodies are effective in B-cell depletion. B cells may modulate T-cell activity through capturing and presenting antigens or may participate in the neogenesis of lymphoid microstructures that amplify and deviate immune responses. Studies exploring which mechanisms are functional in which subset of patients hold the promise of providing new and rational treatment approaches for autoimmune syndromes. |
| publisher |
BioMed Central |
| publishDate |
2003 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165047/ |
| _version_ |
1611367052288720896 |